About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights into sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Core Viewpoint - NanoViricides, Inc. has filed for Orphan Drug Designation for NV-387 as a treatment for Measles with the US FDA, which could provide significant incentives if approved [1] Group 1: Company Developments - The company is a clinical stage leader in developing broad-spectrum antivirals using host-mimetic nanomedicine technology [1] - The application for Orphan Drug Designation (ODD) is aimed at enhancing the treatment options for Measles [1] Group 2: Regulatory Incentives - If granted, the orphan drug designation will provide the company with tax credits for qualified clinical trials [1] - The designation will exempt the company from certain user fees [1] - The company could gain potential market exclusivity for seven years post-approval [1]

Company Overview - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance workflows and improve content delivery [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - The current severe influenza wave highlights the urgent need for broad-spectrum antivirals that can effectively target all influenza viruses and other seasonal respiratory viruses, including RSV and Coronaviruses [1] Company Summary - NanoViricides, Inc. is positioned as a clinical stage leader in the development of innovative broad-spectrum antiviral drugs that are designed to be effective against viruses [1] - The company emphasizes the significance of its antiviral solutions in light of the CDC's classification of this year's flu season as "moderately severe" [1]

Group 1: Market Activity - Several biotech and healthcare companies experienced notable gains in after-hours trading, indicating renewed investor interest in drug development and healthcare services [1] - Zentalis Pharmaceuticals, Inc. (ZNTL) surged 17.65% to close at $4.40, attributed to a recent corporate update that boosted investor confidence in its azenosertib development program [2] - LifeMD, Inc. (LFMD) climbed 12.18% to $4.33 following the announcement of a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability [3] Group 2: Company-Specific Developments - NanoViricides, Inc. (NNVC) advanced 11.11% to $1.24, driven by speculative interest despite no recent news [4] - Intelligent Bio Solutions Inc. (INBS) posted a 9.10% increase, closing at $19.55, continuing to gain momentum from overall investor enthusiasm in the biotech sector [4] - IO Biotech, Inc. (IOBT) rose 6.49% to $0.60, suggesting bargain-hunting activity at lower price levels [5] Group 3: Financing and Agreements - China SXT Pharmaceuticals, Inc. (SXTC) advanced 2.06% to $18.29 after disclosing a definitive agreement for the purchase of 66,666,666 Class A ordinary shares at $0.15 per share, highlighting efforts to strengthen its capital position [6]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for being a forward-looking technology adopter, utilizing technologies to assist and enhance workflows [4] - The company employs automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Group 1 - Proactive specializes in providing fast, accessible, and actionable business and finance news content to a global investment audience [2][3] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team operates from key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Group 2 - Proactive employs technology to enhance workflows and has a forward-looking approach to technology adoption [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Points - NanoViricides, Inc. has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025 [1] - The filing was submitted to the Securities and Exchange Commission (SEC) on November 14, 2025 [1]

Financial Performance - The Company reported a net loss per common share for the three months ended September 30, 2025, with basic and diluted calculations reflecting the potential dilution from outstanding shares[38]. - The Company raised approximately $1,245,000 in net proceeds from the sale of 824,535 shares of common stock at an average price of $1.45 per share from July 1, 2025, to September 30, 2025[58]. - The Company sold 440,453 shares of common stock at an average price of approximately $1.55 per share from October 1, 2025, to November 4, 2025, generating net proceeds of approximately $663,000[73]. - On November 10, 2025, the Company entered into a securities purchase agreement to sell 1,970,000 shares of common stock at an offering price of $1.68 per share, with gross proceeds of approximately $6 million[74]. Research and Development - For the three months ended September 30, 2025, research and development costs related to TheraCour amounted to $539,522, a decrease from $644,527 in the same period of 2024, indicating a reduction of approximately 16.3%[47]. - The Company is dependent on its license agreements with TheraCour, which are critical for the development of its drug candidates[68]. - The Company has entered into multiple license agreements, including a COVID-19 License Agreement with TheraCour, which allows the Company to use proprietary technology for drug development[69]. - The Company will pay KMPL a royalty of 70% of the final invoiced sales of any resulting approved drugs from its clinical test drug candidates for COVID-19 in India[70]. Assets and Liabilities - The total property and equipment as of September 30, 2025, was $15,107,567, an increase from $15,023,250 as of June 30, 2025, reflecting a growth of approximately 0.56%[52]. - The Company’s intangible assets, net, as of September 30, 2025, totaled $314,971, a slight decrease from $317,039 as of June 30, 2025[53]. - The Company’s accumulated depreciation for property and equipment increased to $8,320,111 as of September 30, 2025, from $8,189,359 as of June 30, 2025, indicating an increase of approximately 1.6%[52]. - The Company’s accounts payable to TheraCour as of September 30, 2025, was $663,776, an increase from $584,089 as of June 30, 2025[46]. - As of September 30, 2025, accrued expenses totaled $26,300, an increase from $25,969 as of June 30, 2025[57]. Stock and Equity - The Company has 916,308 shares of Series A preferred stock outstanding, which can convert to 3,207,078 common shares only upon a change of control[39]. - The Company granted Dr. Anil Diwan 10,204 shares of Series A preferred stock, with a non-cash compensation expense of $10,013 recognized for the three months ended September 30, 2025[59]. - The Company issued 117,208 fully vested shares of common stock for consulting and legal services, recording an expense of $173,850 for the three months ended September 30, 2025[62]. - The Company has 5,434 outstanding and exercisable common stock warrants as of September 30, 2025, with a weighted average exercise price of $2.36[64]. Regulatory and Reporting - The Company adopted ASU 2023-07 for segment reporting, effective January 1, 2024, which requires additional disclosures regarding significant segment expenses[42]. - The private placement of Warrants and shares was conducted under an exemption from registration, indicating a strategic move to raise capital without extensive regulatory requirements[75]. - The company qualifies as a smaller reporting company and is not obligated to disclose certain market risk information, reflecting its operational scale[323].